VivoSeq
Oncology

Acute Myeloid Leukemia (AML)

12

Pipeline Programs↗

9

Active Trials↗

13

Companies Involved↗

Acute Myeloid Leukemia (AML) is an emerging landscape with 12 programs across 13 companies. The most active players are iCell Gene Therapeutics, Astellas, Servier. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

25/100

Mech. Concentration

13/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

iCell Gene Therapeutics

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 1S

Servier

1 program

Phase 1Incyte logo

Incyte

1 program

Phase 1K

Kura Oncology, Inc.

1 program

Phase 3Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

9

clinical trials

Recruiting6 · 67%
Active, not recruiting2 · 22%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Phase 1 Trial of Autologous CD123-Directed CAR T-Cells (CART123) as Monotherapy or in Combination With Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
Recruiting·SStephan Grupp MD PhD·Phase 1·NCT07464951·30 enrolled
An Observational Study to Describe the Performance of Caris Chromoseq as Compared to Conventional Cytogenetics, FISH, and NGS Testing Among Patients Receiving the Caris Chromoseq Assay for Hematologic Malignancies
Recruiting·CCaris Science, Inc.·N/A·NCT07680868·300 enrolled
Exposure-Response and Prognostic Analysis of Venetoclax Therapeutic Drug Monitoring in Newly Diagnosed AML
Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT07670130·50 enrolled
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
Recruiting·KKura Oncology, Inc.·Phase 3·NCT07007312·1,300 enrolled
A Clinical Study to Evaluate the Safety and Efficacy of ICG415 CAR-T Cells in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Recruiting·IiCell Gene Therapeutics·Phase 1·NCT07668557·18 enrolled
A Phase 1b Multi-center Study of the FLT3 Inhibitor Gilteritinib in Combination With the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-occurring FLT3/IDH1 or FLT3/IDH2 Mutations
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05756777·18 enrolled
A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT04603001·260 enrolled
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Active, not recruiting·Institut de Recherches Internationales Servier logoInstitut de Recherches Internationales Servier·Phase 3·NCT03173248·146 enrolled
Maintenance Therapy With Lisaftoclax Plus Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse: A Multicenter, Open-Label, Randomized Controlled Trial
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 3·NCT07686965·191 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)